Shares of Allergan PLC. (NYSE:AGN) gapped down prior to trading on Tuesday following insider selling activity. The stock had previously closed at $170.50, but opened at $166.90. Allergan shares last traded at $164.28, with a volume of 7569523 shares traded.
Specifically, insider William Meury sold 11,807 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christopher J. Coughlin acquired 10,000 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The stock was purchased at an average cost of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.36% of the company’s stock.
Several equities research analysts have recently weighed in on AGN shares. Citigroup reissued a “buy” rating and issued a $280.00 price objective on shares of Allergan in a report on Wednesday, September 20th. Deutsche Bank set a $251.00 price objective on Allergan and gave the company a “buy” rating in a report on Tuesday, October 17th. Piper Jaffray Companies set a $227.00 price objective on Allergan and gave the company a “hold” rating in a report on Friday, October 6th. J P Morgan Chase & Co reissued a “buy” rating and issued a $275.00 price objective on shares of Allergan in a report on Monday, October 16th. Finally, Royal Bank Of Canada reissued a “buy” rating and issued a $285.00 price objective on shares of Allergan in a report on Wednesday, September 6th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the stock. Allergan presently has an average rating of “Buy” and a consensus target price of $244.47.
The firm has a market cap of $55,510.00, a PE ratio of 11.02, a PEG ratio of 1.14 and a beta of 1.11. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08.
Allergan (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. Allergan’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.32 earnings per share. research analysts anticipate that Allergan PLC. will post 16.28 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be given a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.70%. The ex-dividend date of this dividend is Thursday, November 16th. Allergan’s payout ratio is -12.39%.
Allergan declared that its board has initiated a stock buyback program on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.
A number of large investors have recently added to or reduced their stakes in AGN. Edgewood Management LLC increased its position in shares of Allergan by 24.3% in the third quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after buying an additional 869,248 shares in the last quarter. Baupost Group LLC MA increased its position in shares of Allergan by 21.9% in the third quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after buying an additional 531,600 shares in the last quarter. Asset Management One Co. Ltd. increased its position in shares of Allergan by 4,852.6% in the third quarter. Asset Management One Co. Ltd. now owns 503,088 shares of the company’s stock valued at $103,108,000 after buying an additional 492,930 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Allergan by 2.2% in the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock valued at $5,551,128,000 after buying an additional 482,220 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Allergan in the third quarter valued at $92,182,000. Hedge funds and other institutional investors own 81.34% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/05/allergan-agn-shares-gap-down-after-insider-selling.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.